Arcturus Therapeutics (ARCT) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View ARCT analyst ratings or view top-rated stocks.

10 equities research analysts have issued 12 month price targets for Arcturus Therapeutics' shares. Their ARCT share price forecasts range from $14.00 to $51.00. On average, they predict the company's stock price to reach $32.25 in the next year. This suggests a possible upside of 20.6% from the stock's current price.
View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts.

Arcturus Therapeutics' stock was trading at $16.96 at the start of the year. Since then, ARCT shares have increased by 57.7% and is now trading at $26.75.
View the best growth stocks for 2023 here.

Arcturus Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,320,000 shares, an increase of 5.7% from the April 30th total of 3,140,000 shares. Based on an average daily trading volume, of 521,600 shares, the days-to-cover ratio is presently 6.4 days. Currently, 13.8% of the company's stock are sold short.
View Arcturus Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ARCT earnings forecast.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its earnings results on Tuesday, March, 28th. The biotechnology company reported $4.33 EPS for the quarter, beating analysts' consensus estimates of ($1.86) by $6.19. The biotechnology company had revenue of $160.29 million for the quarter, compared to the consensus estimate of $134.54 million. Arcturus Therapeutics had a trailing twelve-month return on equity of 36.88% and a net margin of 39.59%.

ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Direxion mRNA ETF (MSGR), Direxion Moonshot Innovators ETF (MOON), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), AXS Green Alpha ETF (NXTE), ETFMG Treatments Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI).

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (17.99%), State Street Corp (8.43%), ARK Investment Management LLC (7.48%), BlackRock Inc. (6.76%), Sumitomo Mitsui Trust Holdings Inc. (5.35%) and Nikko Asset Management Americas Inc. (5.35%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARCT stock can currently be purchased for approximately $26.75.

Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $710.48 million and generates $206 million in revenue each year. The biotechnology company earns $9.35 million in net income (profit) each year or $4.05 on an earnings per share basis.

The company employs 177 workers across the globe.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com.